Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving antidepressant adherence.

Charles B Nemeroff1

  • 1Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA. cnemero@emory.edu

The Journal of Clinical Psychiatry
|January 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of cumulative trauma load on suicide risk and thoughts in trauma-exposed youth over two years.

Journal of affective disorders·2026
Same author

Anhedonia in patients with major depressive disorder (MDD): State-of-the-art consensus review.

Psychiatry research·2026
Same author

Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies.

Journal of clinical psychopharmacology·2026
Same author

Childhood Maltreatment in the Context of Familial Bipolar I Disorder Risk Predicts Major Depressive Disorder in Adolescents.

JAACAP open·2026
Same author

Relationships Among Dementia, Parental Death, and Other Adverse Childhood Experiences: Systematic Review and Meta-Analysis.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same author

Augmenting extinction with counterconditioning strengthens and sustains neural safety representations in PTSD.

Translational psychiatry·2026
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Patients often stop antidepressant treatment due to side effects. Controlled-release antidepressants like venlafaxine XR may improve tolerability and adherence by reducing adverse effects.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Therapeutics

Background:

  • Depressive disorders significantly impact patient quality of life.
  • Antidepressant treatment discontinuation is common, particularly within the first month.
  • Poor tolerability and side effects are primary reasons for non-adherence.

Purpose of the Study:

  • To evaluate the role of controlled-release (CR) antidepressant formulations in improving early treatment tolerability.
  • To compare the side effect profiles of CR antidepressants with their immediate-release (IR) counterparts.
  • To identify factors influencing patient adherence to antidepressant therapy.

Main Methods:

  • Review of clinical data on controlled-release antidepressants.
  • Comparison of pharmacokinetic profiles (peak plasma concentrations) between CR and IR formulations.

Related Experiment Videos

  • Analysis of reported adverse effects for specific CR agents (venlafaxine XR, bupropion SR, paroxetine CR).

    • Main Results:

    • CR antidepressant formulations demonstrate improved tolerability, especially during the critical initial treatment phase.
    • Lower peak plasma drug concentrations in CR formulations contribute to a more favorable side effect profile compared to IR formulations.
    • Specific CR antidepressants, including venlafaxine XR, bupropion SR, and paroxetine CR, show advantages over their IR predecessors in reducing certain adverse effects.

    Conclusions:

    • Controlled-release antidepressant formulations offer a promising strategy to enhance patient adherence by mitigating early-treatment side effects.
    • Optimizing tolerability through CR delivery systems can improve long-term outcomes for patients with depressive disorders.
    • Patient education and physician-patient relationships remain crucial, but formulation choice significantly impacts adherence.